• Samsung Biologics’ third-quarter 2026 operating profit rose 1% year over year to KRW 640.1 billion.
• Revenue increased 18.5% from a year earlier to KRW 1.49 trillion.
• Net income fell 21.2% year over year to KRW 391.1 billion.
• For the first nine months of 2026, revenue climbed 24.4% year over year to KRW 4.07 trillion.
• Operating profit for that period grew 17.3% to KRW 1.81 trillion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261021800344), on October 21, 2026, and is solely responsible for the information contained therein.